Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
We evaluated the in vitro anti-human immunodeficiency virus type 1 (HIV-1) interactions between 1-beta-D-2,6-diaminopurine dioxolane (DAPD) and enfuvirtide (T-20) against clinical isolates sensitive and resistant to reverse transcriptase and protease inhibitors. Interactions between T-20 and DAPD were synergistic to nearly additive, with combination index values ranging from 0.53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients.
Tremblay
Cécile L
CL
Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA. c.tremblay@umontreal.ca
Poulin
Danielle L
DL
Hicks
Jennifer L
JL
Selliah
Subajini
S
Chamberland
Annie
A
Giguel
Françoise
F
Kollmann
Christopher S
CS
Chou
Ting Chao
TC
Dong
Huajin
H
Hirsch
Martin S
MS
D019380:Anti-HIV Agents / Q000494:pharmacology*; D004148:Dioxolanes / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D004357:Drug Synergism; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000494:pharmacology*; D015658:HIV Infections / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D011684:Purine Nucleosides / Q000494:pharmacology*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology
D019380:Anti-HIV Agents; D004148:Dioxolanes; D015700:HIV Envelope Protein gp41; D017320:HIV Protease Inhibitors; D010446:Peptide Fragments; D011684:Purine Nucleosides; D018894:Reverse Transcriptase Inhibitors; D000077560:Enfuvirtide; C098393:amdoxovir